CHD5 expression has been shown to be epigenetically silenced by promoter hypermethylation in a variety of human cancers, including neuroblastomas [17], colorectal cancer [18], breast cancer [19], cervix cancer [19], hepatocarcinoma [19], gastric cancer [20] and lung cancer [21]. The gene discussed is CHD5; the disease is neuroblastoma.